999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
778 331 0962
https://www.essapharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 50
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. David Ross Parkinson M.D. | President, CEO & Director | 814,15k | N/D | 1950 |
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer | 590,39k | N/D | 1957 |
Mr. Peter A. Virsik M.B.A., M.S. | Executive VP & COO | 645,95k | N/D | 1971 |
Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer & Executive VP | 623,93k | N/D | 1961 |
Chandtip Chandhasin | Executive | N/D | N/D | N/D |
Erica Osbourne | Executive | N/D | N/D | N/D |
Erin Rudsinski | Executive | N/D | N/D | N/D |
Loleta Harris | Executive | N/D | N/D | N/D |
Neil Thapar | Executive | N/D | N/D | N/D |
Nkengyal Barber | Executive | N/D | N/D | N/D |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
L'ISS Governance QualityScore di ESSA Pharma Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.